Cipla Stock Slips After Keytruda Biosimilar Deal With Qilu

Cipla’s US arm has tied up with China’s Qilu Pharmaceutical to sell a cheaper version of the cancer drug Keytruda in America. The stock still slipped on Friday, with at least one brokerage staying cautious on the opportunity.

What Cipla and Qilu have agreed

InvaGen Pharmaceuticals Inc, a wholly owned Cipla subsidiary, announced on 3 September 2026 that it has signed an exclusive licensing and supply agreement with Qilu Pharmaceutical Co Ltd for QL2107.

QL2107 is a biosimilar to Keytruda (pembrolizumab). A biosimilar is a near-identical copy of a biological medicine, made once the original drug’s patent protection ends. It works the same way but usually costs less.

The work is split. Qilu handles development, regulatory registration and supply. Cipla USA Inc handles selling the product in the United States, using Cipla’s existing sales network there.

Cipla disclosed the tie-up to the exchanges in a regulatory filing. The companies did not disclose any financial terms. No upfront payment, milestone amounts or profit-share numbers were made public.

Cipla MD and Global CEO Achin Gupta said the deal reflects the company’s “confidence in the long-term potential of biosimilars” and supports its push into oncology. Any launch is subject to US regulatory approval, which has not yet been sought.

Why the stock did not rally

Cipla shares traded lower on Friday, 4 September 2026, even though the announcement was a positive one on paper.

The gap between the news and the price reaction comes down to timing and competition. QL2107 is still a development-stage product. Even in a good scenario, revenue from it is several years away.

Morgan Stanley stays cautious

Morgan Stanley has kept an Underweight rating on Cipla with a target price of ₹1,218, according to brokerage commentary circulated on 4 September 2026.

Two terms worth explaining here. “Underweight” is a brokerage’s way of saying it expects the stock to do worse than the broader market. A “target price” is that firm’s own estimate of where the stock could trade over roughly 12 months. It is not a promise, and other brokerages hold very different views on Cipla.

The concern flagged is that the pembrolizumab biosimilar market is already crowded, which limits how much any one late entrant can earn from it.

The 2028 patent cliff everyone is racing towards

Keytruda is Merck’s PD-1 immunotherapy and the world’s highest-selling drug by revenue. Global sales were around $29.5 billion in 2024, roughly ₹2.8 lakh crore at the current exchange rate of about ₹94.73 to the dollar.

Its core US composition-of-matter patent is expected to expire in 2028. That is the patent cliff, the point after which rivals can legally sell copies.

The size of that prize has pulled in a queue of developers. At least seven companies have publicly disclosed active pembrolizumab biosimilar programmes, including Samsung Bioepis, Amgen, Sandoz, Celltrion and Bio-Thera, alongside several Indian manufacturers.

Merck is also defending its turf. It won US approval in September 2025 for Keytruda Qlex, an under-the-skin version of the drug, which some analysts expect will retain a meaningful share of sales even after biosimilars arrive.

So Cipla is entering a race that is already well populated, against an originator that has spent years preparing for it.

Second China-linked oncology deal in a week

This is not a one-off move. Earlier the same week, Cipla licensed TQB2102, a HER2 bispecific antibody-drug conjugate for cancer, from China’s Sino Biopharma for India, South Africa and five other emerging markets.

Two in-licensing deals in a few days points to a clear strategy. In-licensing means buying the rights to sell someone else’s drug rather than developing it in-house. It is faster and cheaper upfront, but the economics are shared with the partner.

For investors tracking pharma names in their demat account, that trade-off is the thing to weigh: a broader oncology basket, built with lower research spending, but with thinner margins than a self-developed product would carry.

What to watch next

The next real checkpoints are regulatory, not commercial. Watch for a US filing for QL2107, any disclosure of deal economics in Cipla’s quarterly results, and how many rival pembrolizumab biosimilars reach the US Food and Drug Administration ahead of it.

Until then, the announcement changes Cipla’s pipeline more than it changes its near-term earnings. Investors following the stock can track it live through any SEBI-registered online trading platform during market hours, 9:15 AM to 3:30 PM IST.

Investments in the securities market are subject to market risks. Read all related documents carefully before investing. This article is for information only and is not investment advice.